How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

9,526 results for

E/M Medical Decision Making

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative E (PubMed)

Patient-Reported Health-Related Quality of Life Is a Predictor of Outcomes in Ambulatory Heart Failure Patients Treated With Left Ventricular Assist Device Compared With Medical Management: Results From the ROADMAP Study (Risk Assessment and Comparative E The prospective observational ROADMAP study (Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management) demonstrated that ambulatory advanced heart failure patients selected for left ventricular (...) assist device (LVAD) were more likely to be alive at 1 year on original therapy with ≥75-m improvement in 6-minute walk distance compared with patients assigned to optimal medical management. Whether baseline health-related quality of life (hrQoL) resulted in a heterogeneity of this treatment benefit is unknown.Patient-reported hrQoL was assessed with EuroQol questionnaire and visual analogue scale (VAS). We aimed to identify predictors of event-free survival and survival with acceptable hrQoL (VAS

Full Text available with Trip Pro

2017 Circulation. Heart failure

42. Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer

Added value of using gene-expression signature for adjuvant chemotherapy decisions in early breast cancer Nov2015 © EUnetHTA, 2015. Reproduction is authorised provided EUnetHTA is explicitly acknowledged EUnetHTA Joint Action 3 WP4 Rapid assessment of other technologies using the HTA Core Model ® for Rapid Relative Effectiveness Assessment MammaPrint ® Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast cancer Project ID (...) , patients can be divided into low- and high-risk groups, which in turn supports clinical decision- making for adjuvant treatment. MammaPrint ® has been prospectively validated for use in early- stage breast cancer patients with tumours 5% or HR 5% at =3 years follow-up and a GRADE B survival improvement as between 3% and 5%. In the case that mature survival data is not available, GRADE A clinical benefit is assigned when DFS improvements are found in which the HR is 70 19 (0.7) 11 (1.9) 16 (1.0) 10 (0.6

2018 EUnetHTA

43. E-learning of evidence-based healthcare (EBHC) to increase EBHC competencies in healthcare professionals

learning is most effective in increasing evidence-based health care competencies of health workers E-learning is a useful strategy to increase EBHC knowledge and skills, and when combined with face-to-face learning, to increase EBHC attitude and behaviour. The review in brief Evidence-based health care (EBHC) is decision-making for health care, informed by the best research evidence. Doctors, nurses and allied health professionals need to have the necessary knowledge and skills to apply EBHC. The use (...) , CONDITION OR ISSUE The need for evidence-based health care competencies Evidence-based medicine (EBM), introduced in 1991, has its roots in the field of clinical epidemiology and was listed as “one of the 15 greatest medical milestones since 1840” in the British Medical Journal (Montori & Guyatt, 2008). The most commonly used definition of evidence-based medicine (EBM) describes it as “the conscientious, explicit and judicious use of the current best evidence in making decisions about the care

2017 Campbell Collaboration

44. Intrapartum care for women with existing medical conditions or obstetric complications and their babies

on consent and mental capacity), and safeguarding. Supporting women to make decisions about their care is particularly important during the intrapartum period. Healthcare professionals should ensure that women have the information they need to make decisions and to give consent in line with General Medical Council (GMC) guidance and the 2015 Montgomery ruling. 1.1 Information for women with existing medical conditions 1.1.1 Clarify with women with existing medical conditions whether and how they would (...) an individualised plan for intrapartum care. The plan should be: formulated by following the principles of shared decision making outlined in the NICE guideline on patient experience in adult NHS services reviewed with the woman and her birth companion(s) as early as possible throughout pregnancy and on admission for birth updated with the woman if her medical condition changes during pregnancy shared with the woman's GP and teams providing her antenatal and intrapartum care. 1.2.2 For pregnant women

2019 National Institute for Health and Clinical Excellence - Clinical Guidelines

45. A resource for developing an evidence synthesis report for policy-making

A resource for developing an evidence synthesis report for policy-making Leena Eklund Karlsson | Ryoko Takahashi HEALTH EVIDENCE NETWORK SYNTHESIS REPORT 50 A resource for developing an evidence synthesis report for policy-makingThe Health Evidence Network HEN – the Health Evidence Network – is an information service for public health decision-makers in the WHO European Region, in action since 2003 and initiated and coordinated by the WHO Regional Office for Europe under the umbrella (...) of the European Health Information Initiative (a multipartner network coordinating all health information activities in the European Region). HEN supports public health decision-makers to use the best available evidence in their own decision-making and aims to ensure links between evidence, health policies and improvements in public health. The HEN synthesis report series provides summaries of what is known about the policy issue, the gaps in the evidence and the areas of debate. Based on the synthesized

2017 WHO Health Evidence Network

46. Does advance care planning alter management decisions made by healthcare professionals?

/AdvanceCarePlanning.pdf Although there is a significant body of literature informing the development and implementation of advance care planning processes, the impact of completed advance care plans on the decision making of healthcare professionals at the time of a medical event is less clear. Evidence for the impact of advance care planning programmes on the quality of care provided is required to underpin funding and delivery of integrated advance care planning across care settings. The purpose of this rapid (...) in the ACP, there is no direct correlation with preferences expressed in the ACP and outcomes, so the specific impact of stated patient preferences on outcome is unclear Cohen- Mansfield et al 2008 Study Setting & Design – A single care home, USA; Retrospective observational study. Study Objective To ascertain the role that advance directives (ADs) play in actual decision making in nursing homes at the time of a medical event. Participants 6 physicians and 3 nurses 64 patients with an AD in place

2017 Palliative Care Evidence Review Service (PaCERS)

47. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer

/JCO.2017.74.0472 Journal of Clinical Oncology - published online before print July 10, 2017 PMID: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update x Ian Krop , x Nofisat Ismaila , x Fabrice Andre , x Robert C. Bast , x William Barlow , x Deborah E. Collyar , x M. Elizabeth Hammond , x Nicole M. Kuderer , x Minetta C. Liu , x Robert G. Mennel , x (...) Catherine Van Poznak , x Antonio C. Wolff , and x Vered Stearns Ian Krop, Dana-Farber Cancer Institute, Boston, MA; Nofisat Ismaila, American Society of Clinical Oncology, Alexandria, VA; Fabrice Andre, Institute Gustave Roussy, Paris, France; Robert C. Bast, The University of Texas MD Anderson Cancer Center, Houston; Robert G. Mennel, Baylor University Medical Center, Texas Oncology PA, Dallas, TX; William Barlow, Cancer Research and Biostatistics, Seattle, WA; Deborah E. Collyar, Patient Advocates

2017 American Society of Clinical Oncology Guidelines

48. Moving Toward a Recovery-Oriented System of Care: A Resource for Service Providers and Decision Makers

Moving Toward a Recovery-Oriented System of Care: A Resource for Service Providers and Decision Makers www.ccsa.ca • www.ccdus.ca Moving Toward a Recovery- Oriented System of Care A Resource for Service Providers and Decision Makers September 2017 Moving Toward a Recovery- Oriented System of Care A Resource for Service Providers and Decision Makers Suggested citation: Canadian Centre on Substance Use and Addiction (2017). Moving Toward a Recovery-Oriented System of Care: A Resource for Service (...) Providers and Decision Makers. Ottawa, Ont.: Author. © Canadian Centre on Substance Use and Addiction, 2017. CCSA, 500–75 Albert Street Ottawa, ON K1P 5E7 Tel.: 613-235-4048 Email: recovery@ccsa.ca Production of this document has been made possible through a financial contribution from Health Canada. The views expressed herein do not necessarily represent the views of Health Canada. This document can also be downloaded as a PDF at www.ccsa.ca Ce document est également disponible en français sous le

2017 Canadian Centre on Substance Abuse

49. Deceased organ and tissue donation after medical assistance in dying and other conscious and competent donors: guidance for policy

. This avoids the potential distress of making a request or obtaining consent for donation only to have to inform the patient that they are medically or logistically ineligible. Conversations about donation The decision to proceed with MAiD or WLSM must be separate from, and must precede, the decision to donate. Treating physicians, MAiD providers and MAiD assessors should be educated on how to respond to inquiries concerning organ donation. This should include how the decision to donate may affect the end (...) providers and policy-makers. This document is intended to inform policies related to offering organ and tissue donation to patients who have made a decision that will lead to imminent death. These are conscious, competent patients who have chosen to withdraw mechanical ventilation, including invasive or noninvasive GUIDELINE | GUIDANCE FOR POLICY CPD Deceased organ and tissue donation after medical assistance in dying and other conscious and competent donors: guidance for policy James Downar MDCM MHSc

2019 CPG Infobase

50. Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder

Evidence Brief - Barriers and Facilitators to Use of Medications for Opioid Use Disorder 4 August 2019 Prepared for: Department of Veterans Affairs Veterans Health Administration Health Services Research & Development Service Washington, DC 20420 Prepared by: Evidence Synthesis Program (ESP) Coordinating Center Portland VA Medical Center Portland, OR Mark Helfand, MD, MPH, MS, Director Evidence Brief: Barriers and Facilitators to Use of Medication s for Opioid Use Disorder Authors: Katherine (...) Mackey, MD, MPP Stephanie Veazie, MPH Johanna Anderson, MPH Donald Bourne, MPH Kim Peterson, MS Evidence Synthesis Program Evidence Brief: Barriers and Facilitators to Use of Medications for OUD Evidence Synthesis Program i PREFACE The VA Evidence Synthesis Program (ESP) was established in 2007 to provide timely and accurate syntheses of targeted healthcare topics of importance to clinicians, managers, and policymakers as they work to improve the health and healthcare of Veterans. These reports help

2019 Veterans Affairs Evidence-based Synthesis Program Reports

51. Management of Cancer Medication-Related Infusion Reactions

practice guideline, informed by best available evidence and expert consensus, was developed to help standardize the prevention and management of IRs across the province. Definitions The term IR is a broad classification; therefore, a standardized definition is needed to facilitate accurate documentation of reactions and provide guidance on treatment and re-challenge decision-making. An infusion reaction (IR) is any adverse sign or symptom that occurs during the infusion of a medication or within (...) Management of Cancer Medication-Related Infusion Reactions Management of Cancer Medication- Related Infusion Reactions Care has been taken in the preparation of the information contained in this report. Nonetheless, any person seeking to apply or consult the report is expected to use independent medical judgment in the context of individual clinical circumstances or seek out the supervision of a qualified clinician. Cancer Care Ontario makes no representation or guarantees of any kind

2019 Cancer Care Ontario

52. Erratum to: What Middle Phalanx Base Fracture Characteristics are Most Reliable and Useful for Surgical Decision-making? (PubMed)

Erratum to: What Middle Phalanx Base Fracture Characteristics are Most Reliable and Useful for Surgical Decision-making? 26842233 2016 06 30 2016 03 23 1528-1132 474 4 2016 Apr Clinical orthopaedics and related research Clin. Orthop. Relat. Res. Erratum to: What Middle Phalanx Base Fracture Characteristics are Most Reliable and Useful for Surgical Decision-making? 1080-1 10.1007/s11999-016-4728-0 Janssen Stein J SJ Hand and Upper Extremity Service, Department of Orthopaedic Surgery, Yawkey (...) Barreto C J R C Nyszkiewicz R R Sodha S S Ruchelsman D D Bonatz E E Walbeehm E T E Schumer E D E Suarez F F DeSilva G G Gaston R G R Hernandez G R G Nancollas M M Hofmeister E E Fanuele J C J Boretto J G J Choueka J J Huang J I J Wolf J M JM Erickson J M J Howlett J J Taras J J Wint J J Kakar S S Chivers K K Prommersberger K J KJ Lee K K Rumball K M K Kraan G A G Weiss L L Lattanza L L de Mendonça L A L Jr Paz L L Catalano L L 3rd Calcagni M M McAuliffe J J Darowish M M Costanzo R M R Wood M M MM

Full Text available with Trip Pro

2016 Clinical Orthopaedics and Related Research

53. Shared Decision-Making in Intensive Care Units. Executive Summary of the American College of Critical Care Medicine and American Thoracic Society Policy Statement (PubMed)

.201602-0269ED Kon Alexander A AA 1 Naval Medical Center San Diego San Diego, California. 2 University of California San Diego San Diego, California. Davidson Judy E JE 3 University of California Health System San Diego, California. Morrison Wynne W 4 Children's Hospital of Philadelphia Philadelphia, Pennsylvania. Danis Marion M 5 National Institutes of Health Bethesda, Maryland and. White Douglas B DB 6 University of Pittsburgh School of Medicine Pittsburgh, Pennsylvania. eng Journal Article Practice (...) Guideline United States Am J Respir Crit Care Med 9421642 1073-449X AIM IM Clinical Decision-Making methods Critical Care methods Humans Intensive Care Units Societies, Medical United States 2016 4 21 6 0 2016 4 21 6 0 2017 12 27 6 0 ppublish 27097019 10.1164/rccm.201602-0269ED PMC4910896 Chest. 2007 Sep;132(3):748-51; discussion 755-6 17873188 Crit Care Med. 2004 Aug;32(8):1781-4 15286559 Virtual Mentor. 2012 Jul 01;14(7):545-50 23351289 Health Aff (Millwood). 2007 May-Jun;26(3):716-25 17485749 Crit

Full Text available with Trip Pro

2016 American Journal of Respiratory and Critical Care Medicine

54. Shared decision making in antipsychotic prescribing: the perspective of psychiatrists

Shared decision making in antipsychotic prescribing: the perspective of psychiatrists Shared decision making in antipsychotic prescribing Search National Elf Service Search National Elf Service » » » » Shared decision making in antipsychotic prescribing: the perspective of psychiatrists Jul 11 2014 Posted by Despite the growth in psychosocial interventions for people with psychosis (specifically cognitive behavioural therapy and family interventions), antipsychotic medication remains (...) management as a collaborative process between prescriber and service user. This was developed into a manualised intervention that mental health practitioners could be trained to deliver, known as Medication Management (Gray, 2004), which had shared decision-making at it’s core. Indeed, the Recovery movement in mental health is driving the need for all mental health practitioners to work in collaboration, developing a shared understanding of the issues, and working together to solve problems

2014 The Mental Elf

55. Simplified guideline for prescribing medical cannabinoids in primary care

Simplified guideline for prescribing medical cannabinoids in primary care Vol 64: FEBRUARY | FÉVRIER 2018 | Canadian Family Physician | Le Médecin de famille canadien 111 CLINICAL PRACTICE GUIDELINES Abstract Objective To develop a clinical practice guideline for a simplified approach to medical cannabinoid use in primary care; the focus was on primary care application, with a strong emphasis on best available evidence and a promotion of shared, informed decision making. Methods The Evidence (...) , and content is offered to support shared, informed decision making. Conclusion This simplified medical cannabinoid prescribing guideline provides practical recommendations for the use of medical cannabinoids in primary care. All recommendations are intended to assist with, not dictate, decision making in conjunction with patients. Editor’s key points ? This simplified prescribing guideline was developed with a primary care focus. Guideline contributors were selected based on profession, practice setting

2018 CPG Infobase

56. PEER Simplified Guideline: Medical Cannabinoids

PEER Simplified Guideline: Medical Cannabinoids PEER SIMPLIFIED GUIDELINE: MEDICAL CANNABINOIDS Clinical Practice Guideline | January 2018 These recommendations are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. They should be used as an adjunct to sound clinical decision making. OBJECTIVE Primary care physicians can incorporate medical cannabinoids into their prescribing practices by being (...) informed with best available evidence and using a simplified, shared decision-making approach with their patients. TARGET POPULATION Adults (i.e., 18 years of age and older) EXCLUSIONS Children RECOMMENDATIONS See recommendations summary algorithm in Appendix A. GENERAL RECOMMENDATION X DO NOT prescribe medical cannabinoids for most medical conditions. There is a lack of evidence of benefit, and known harms. [Strong recommendation] Note: Possible exceptions are described elsewhere in this document

2018 Toward Optimized Practice

57. The Patient Centred Medical Home: barriers and enablers to implementation

teamwork. Staff experience: Without adequate staff/staff support, the model cannot be adequately implemented or sustained. • Inadequate staff • Staff dissatisfied with roles • Staff burnout. • Participatory decision-making • Having adequate staff • Trust-building exercises. Time: Major change initiatives such as PCMH take time. Beyond implementation, many of the facets of PCMH take time (e.g. preventative measures, care coordination). • Inadequate time allocated to transition to a PCMH • Inadequate (...) time allocated to undertake comprehensive assessments and holistic interventions. • Recognition of the time it takes to make changes • Separate visits for preventive care • The use of electronic medical records (provided they have a user-friendly interface). Health information technology: Benefits of health information technology are widely • Time, effort and other resources for implementation. • Available technology is inadequate to support quality initiatives • Training, specifically, • Applied

2018 Sax Institute Evidence Check

58. A decision aid for women considering further chemotherapy for refractory or resistant ovarian cancer

multidisciplinary team and your family about the options available to you. It is another resource you can use to ensure that you are making a decision that is right for you. The following sections discuss recurrent, resistant and refractory ovarian cancer and treatment options. They contain a lot of medical information and new terms. If you are ? nding it dif? cult to read all at once, it may be helpful to come back and re-read it again at another time. There is also a glossary of terms on page 62.REFRACTORY (...) . Medical professionals also use the terms “resistant” or “refractory” to distinguish between different types of recurrent ovarian cancer based on the time when the cancer returned. Time to recurrence is the time between when your last chemotherapy cycle ? nished and the diagnosis of recurrent ovarian cancer. MAKING A DECISION THAT’S RIGHT FOR YOU 9 TYPES OF RECURRENT OV ARIAN CANCER Refractory: When cancer continues to grow during chemotherapy. Resistant: When cancer returns in less than 6 months from

2015 SickKids Supportive Care Guidelines

59. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

. No consensus E: In patients with mild to moderate CD, the consensus group does not make a recommendation (for or against) regarding the use of antibiotics to maintain clinical remission. No consensus F: In male patients with CD the consensus group does not make a recommendation (for or against) regarding a thiopurine to maintain remission. No consensus G: In patients with mild to moderate CD, the consensus group does not make a recommendation (for or against) regarding methotrexate monotherapy to induce (...) it with a thiopurine to maintain a durable clinical remission. No consensus L: In patients with CD who have achieved a clinical remission with anti-TNF therapy, the consensus group does not make a recommendation (for or against) regarding assessment for mucosal healing within the first year to determine the need to modify therapy. No consensus M: In patients with moderate to severe CD who fail to achieve or maintain clinical remission with an anti-TNF–based therapy, the consensus group does not make

2019 Canadian Association of Gastroenterology

60. Immediate postpartum long-acting reversible contraception for women at high risk for medical complications

, and appropriatelybillforservices.Expandingtherangeofhealth- careprofessionalswhoaretrainedtocounselwomenandto insertLARCdevicescouldreducetheburdenonphysicians. ProgramstotrainnursesormidwivesinLARCcounselingas wellasplacementmaybeamodelthatcanbeintegratedinto busy outpatient and inpatient settings. The MFM subspe- cialist can serve as consultant for these teams to help with contraceptive decision making for women with complex medical conditions. Having obstetric care provider cham- pionscanleadtoimplementationofsustainableprogramsin (...) Immediate postpartum long-acting reversible contraception for women at high risk for medical complications SocietyforMaternal-FetalMedicine(SMFM) ConsultSeries#48:Immediatepostpartum long-actingreversiblecontraceptionforwomen athighriskformedicalcomplications Society for Maternal-Fetal Medicine (SMFM); Laura K. Vricella, MD; Lori M. Gawron, MD, MPH; Judette M. Louis, MD, MPH The Society of Family Planning (SFP) endorses this document. The American College of Obstetricians and Gynecologists

2019 Society for Maternal-Fetal Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>